Key facts
- This page summarizes Kathleen D. Scott's Form 4 filing for NKGen Biotech, Inc. (NKGN).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 10 Dec 2024, 21:56.
Kathleen D. Scott - 06 Dec 2024 Form 4 Insider Report for NKGen Biotech, Inc. (NKGN)
- Reporting relationship
- Director
- Issuer ticker
- NKGN
- Reported as of
- 06 Dec 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 10 Dec 2024, 21:56:38 UTC
- Prior SEC filing
- 17 Oct 2024
- Next SEC filing
- 03 Jan 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Paul Y. Song, as Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Kathleen D. Scott filed Form 4 for NKGen Biotech, Inc. (NKGN) on 10 Dec 2024.
Change
- Previous filing in this sequence was filed on 17 Oct 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
NKGN
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +300,000
- Change %
- Price
- $0.000000
- Shares after
- 300,000
- Date
- 06 Dec 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 300,000
- Exercise price
- $1.62
- Footnotes
- F1
NKGN
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +500,000
- Change %
- Price
- $0.000000
- Shares after
- 500,000
- Date
- 06 Dec 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 500,000
- Exercise price
- $0.4380
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
On December 6, 2024, the Reporting Person was granted 300,000 options pursuant to the Company's 2023 Equity Incentive Plan, with 40% vesting immediately as of the grant date, and the remaining options vesting in 20 equal installments on the sixth day of each month, beginning January 6, 2025, and ending August 6, 2026, subject to the Reporting Person's continued service with the Issuer on each respective vesting date.
Footnote F2
On December 6, 2024, the Reporting Person was granted 500,000 options pursuant to the Company's 2023 Equity Incentive Plan, vesting in 36 equal installments on the sixth of each month, beginning January 6, 2025, and ending December 6, 2027, subject to the Reporting Person's continued service with the Issuer on each respective vesting date.